Conference Reports for NATAP

The Liver Meeting Boston MA November 2019 Back

A Phase 2 Study of Lonafarnib, Ritonavir & Peginterferon Lambda for 24 Weeks: Interim End-of-Treatment Results from the LIFT HDV Study       AASLD 2019 Nov 8-12 Boston   Christopher Koh, MD MHSc FAASLD National Institute of Diabetes & Digestive & Kidney Diseases